Cell MedX Corp Introduces Ongoing eBalance Pro Trial Observations Online
LAS VEGAS, NV--(Marketwired - Jan 25, 2016) - Cell MedX Corp. (OTCQB: CMXC) ("Cell MedX" or the "Company"), a development stage company focused on the commercialization of therapeutic devices for patients with diseases such as diabetes, today advises it now offers access to ongoing observations of actual eBalance Professional (Pro) Series users.
The observational reports can be found at www.cellmedx.com/observations and will be updated frequently. New users are being actively solicited to participate in the ongoing research and the Company expects the data will prove extremely useful to its development aims.
The eBalance Pro device is designed to study targeted effects on glucose control, increased insulin sensitivity and insulin resistance, abatement of diabetic neuropathy, accelerated wound healing as well as pain management for both non-diabetic and diabetic patients.
Cell MedX President and CEO Mr. Frank McEnulty states, "Our early results propelled us to commence the manufacture of additional units and to get them in use as quickly as possible. We are receiving excellent user responses to the device and its documented efficacy is on track and improvements will be duly noted as we increase our user base. As noted previously, we anticipate that practical use of the units will translate into the potential for increased interest and future demand as we move forward towards commercialization. We thank everyone for their interest and are delighted to be moving ahead."
About Cell MedX Corp. (OTCQB: CMXC)
Cell MedX Corp. is a development stage company focused on the commercialization of therapeutic products for patients with diseases such as diabetes by developing technologies to help manage the illness and related complications. For more information go to: www.cellmedx.com and visit us on Facebook.
The observational reports can be found at www.cellmedx.com/observations and will be updated frequently. New users are being actively solicited to participate in the ongoing research and the Company expects the data will prove extremely useful to its development aims.
The eBalance Pro device is designed to study targeted effects on glucose control, increased insulin sensitivity and insulin resistance, abatement of diabetic neuropathy, accelerated wound healing as well as pain management for both non-diabetic and diabetic patients.
Cell MedX President and CEO Mr. Frank McEnulty states, "Our early results propelled us to commence the manufacture of additional units and to get them in use as quickly as possible. We are receiving excellent user responses to the device and its documented efficacy is on track and improvements will be duly noted as we increase our user base. As noted previously, we anticipate that practical use of the units will translate into the potential for increased interest and future demand as we move forward towards commercialization. We thank everyone for their interest and are delighted to be moving ahead."
About Cell MedX Corp. (OTCQB: CMXC)
Cell MedX Corp. is a development stage company focused on the commercialization of therapeutic products for patients with diseases such as diabetes by developing technologies to help manage the illness and related complications. For more information go to: www.cellmedx.com and visit us on Facebook.